Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ANTs SOFTWARE.COM (ANTS) -- Ignore unavailable to you. Want to Upgrade?

To: Crandell Addington who wrote (488)	1/3/2001 6:00:31 PM
From: Sir Auric Goldfinger	Read Replies (1) \| Respond to of 607

Jeez crabeeee, ANTS is the only name that did not participate in the Fed rally today. Were you selling?

To: Crandell Addington who wrote (488)	1/23/2001 8:27:20 PM
From: StockDung	Respond to of 607

Stocks Climb on High Hopes January 23, 2001 Stocks Climb on High Hopes The Nasdaq posts its strongest close in six weeks as investors shrug off a poor outlook from Texas Instruments Inc.

To: Crandell Addington who wrote (488)	3/23/2002 7:58:58 PM
From: StockDung	Respond to of 607

crabby-dicks.com

To: Crandell Addington who wrote (488)	8/23/2002 12:40:38 AM
From: StockDung	Read Replies (1) \| Respond to of 607

ONLY 21 DOLLARS TO GO AND YOU WILL BE EVEN ANTS - ANTS SOFTWARE INC Last Price: 1.02 at 15:41 EDT Change: Up 0.22 (+27.50%) High: 1.14 at 11:15 EDT Low: 0.80 at 9:30 EDT Open: 0.80 Previous Close: 0.80 on 8/21 Volume: 275,400 Currency Units: US Dollar Exchange/Delay: OTCBB: 15 minutes Confirm all data with your broker or financial advisor before trading. Data by: S&P ComStock

To: Crandell Addington who wrote (488)	8/26/2003 11:22:14 AM
From: StockDung	Respond to of 607

"the purpose of selling and distributing the ANTs Data Server in Poland, Russia, the Czech Republic, and the European Common Market." 8-k filing today: ITEM 5. Other Events and Regulation FD Disclosure On August 22, 2003 ANTs software inc. signed a letter of intent (the "Letter") with Net Soft Systems, Inc. of Vancouver, British Columbia, Canada. Pursuant to the terms of the Letter, both parties agreed to pursue a joint venture agreement which would establish a joint venture organized for the purpose of selling and distributing the ANTs Data Server in Poland, Russia, the Czech Republic, and the European Common Market. pinksheets.com

To: Crandell Addington who wrote (488)	12/18/2005 4:11:41 PM
From: StockDung	Respond to of 607

Released by FDA: 3/7/00. Posted by FDA: 3/16/00 Joseph B. Nester President Ozelle Pharmaceuticals, Inc. 11825 IH 10 West, Ste 213 San Antonio, TX 78230 Re: Anvirzel TM IND 58,345 MACMIS lD# 8776 Dear Mr. Nester: It has come to the attention of the Division of Drug Marketing, Advertising, and Communications (DDMAC) that Ozelle Pharmaceuticals (Ozelle) is promoting Anvirzel prior to approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act) and its implementing regulations (see 21 CFR 312.7). Ozelle’s website makes numerous claims regarding the safety and efflcacy of Anvirzel. These claims are based solely upon preliminary and inconclusive data since the clinical investigation of Anvirzel is in a preliminary stage; neither the safety nor efficacy of the drug has been demonstrated by substantial evidence (i.e., adequate and well-controlled studies). Therefore, the information on the website is in violation of the Act and its implementing regulations because it promotes an investigational new drug. Following are selected statements from the website that promote the drug as safe and/or effective: - Objective clinical responses in these cases were documented, including complete responses, partial responses, and stabilization of disease. Anvirzel exerted a very consistent palliative effect on patients treated for four to six weeks. These patients experienced increased energy, diminished pain, decreased need for analgesia, as well as an enhanced sense of well being. The drug has shown very positive responses in almost all of these cases. Particularly evident has been a dramatic increase in patients’ Quality of Life and tumor arrestment. Experience shows that Anvirzel is a multi-mechanism drug that uniquely modulates the immune system and has cytotoxic activity that attacks cancer cells. Additionally, the drug produces yet unexplained pain reduction and/or pain remission. There have been no perceived negative side effects noted with the use of Anvirzel to date. Since a New Drug Application (NDA) for Anvirzel has not been approved for marketing by the Food and Drug Administration (FDA), the dissemination of information by Ozelle that represents in a promotional context that Anvirzel is safe and effective constitutes promotion of an investigational drug, in violation of the Act. DDMAC requests that the distribution and use of materials that promote Anvirzel prior to approval cease immediately, including but not limited to, removal of violative information from the Ozelle website. Ozelle should submit in writing, on or before March 21, 2000, a description of the steps that will be taken to comply with the above request. Ozelle should direct its response to the undersigned by facsimile at (301) 594-6771, or by written communication at the Division of Drug Marketing, Advertising, and Communications, HFD-42; Room 17B-20; 5600 Fishers Lane; Rockville, MD 20857. ODMAC reminds Ozelle that only written communications are considered official. In all future correspondence regarding this matter, please refer to MACMIS lD# 8776 and IND 58,345 Sincerely, Jean-Ah Choi, Pharm.D. Regulatory Review Officer Division of Drug Marketing, Advertising, and Communications